301 related articles for article (PubMed ID: 18504432)
1. AKT1(E17K) in human solid tumours.
Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
[TBL] [Abstract][Full Text] [Related]
2. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
[TBL] [Abstract][Full Text] [Related]
3. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
Shoji K; Oda K; Nakagawa S; Hosokawa S; Nagae G; Uehara Y; Sone K; Miyamoto Y; Hiraike H; Hiraike-Wada O; Nei T; Kawana K; Kuramoto H; Aburatani H; Yano T; Taketani Y
Br J Cancer; 2009 Jul; 101(1):145-8. PubMed ID: 19491896
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.
Kim MS; Jeong EG; Yoo NJ; Lee SH
Br J Cancer; 2008 May; 98(9):1533-5. PubMed ID: 18392055
[TBL] [Abstract][Full Text] [Related]
5. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
6. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
Ismail SI; Mahmoud IS; Msallam MM; Sughayer MA
Leuk Res; 2010 Jun; 34(6):824-6. PubMed ID: 20022634
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
[TBL] [Abstract][Full Text] [Related]
8. A new mutational AKTivation in the PI3K pathway.
Brugge J; Hung MC; Mills GB
Cancer Cell; 2007 Aug; 12(2):104-7. PubMed ID: 17692802
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
[TBL] [Abstract][Full Text] [Related]
10. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.
Lauring J; Cosgrove DP; Fontana S; Gustin JP; Konishi H; Abukhdeir AM; Garay JP; Mohseni M; Wang GM; Higgins MJ; Gorkin D; Reis M; Vogelstein B; Polyak K; Cowherd M; Buckhaults PJ; Park BH
Oncogene; 2010 Apr; 29(16):2337-45. PubMed ID: 20101210
[TBL] [Abstract][Full Text] [Related]
11. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
[TBL] [Abstract][Full Text] [Related]
12. AKT Inhibition in Solid Tumors With AKT1 Mutations.
Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
[TBL] [Abstract][Full Text] [Related]
13. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
Rudolph M; Anzeneder T; Schulz A; Beckmann G; Byrne AT; Jeffers M; Pena C; Politz O; Köchert K; Vonk R; Reischl J
BMC Cancer; 2016 Aug; 16():622. PubMed ID: 27515171
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
Mancini ML; Lien EC; Toker A
Oncotarget; 2016 Apr; 7(14):17301-13. PubMed ID: 27004402
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
[TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt pathway mutations in retinoblastoma.
Cohen Y; Merhavi-Shoham E; Avraham-Lubin BC; Savetsky M; Frenkel S; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5054-6. PubMed ID: 19420344
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
Landgraf KE; Pilling C; Falke JJ
Biochemistry; 2008 Nov; 47(47):12260-9. PubMed ID: 18954143
[TBL] [Abstract][Full Text] [Related]
18. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
19. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.
Malanga D; Scrima M; De Marco C; Fabiani F; De Rosa N; De Gisi S; Malara N; Savino R; Rocco G; Chiappetta G; Franco R; Tirino V; Pirozzi G; Viglietto G
Cell Cycle; 2008 Mar; 7(5):665-9. PubMed ID: 18256540
[TBL] [Abstract][Full Text] [Related]
20. Absence of AKT1 mutations in glioblastoma.
Bleeker FE; Lamba S; Zanon C; van Tilborg AA; Leenstra S; Troost D; Hulsebos T; Vandertop WP; Bardelli A
PLoS One; 2009 May; 4(5):e5638. PubMed ID: 19461960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]